Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring [0.03%]
评论：risankizumab治疗难治性克罗恩病从中位疗效到战略性定位和早期监测
Kenneth Ernest-Suárez,Frank Hoentjen
Kenneth Ernest-Suárez
Editorial: Rifaximin and the Gut-Liver-Brain Axis-Progress and Prudence. Authors' Reply [0.03%]
编辑部： rifaximin与肠肝脑轴的进展和慎重-作者回复
Hiroki Inada,Yasuhito Tanaka
Hiroki Inada
Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders [0.03%]
meta分析：高移动性血管水肿病综合征和高移动性谱系障碍的慢性胃肠症状及共病状况
Dmitrii Kulin,Gerald Holtmann,Thomas Fairlie et al.
Dmitrii Kulin et al.
Background: Patients with Ehlers-Danlos syndrome (EDS)/hypermobility spectrum disorders (HSD) report higher rates of chronic gastrointestinal (GI) symptoms, disorders of gut-brain interaction (DGBI), and extraintestinal c...
Meta-Analysis: Redefining Liver Disease Risk in Heterozygous Alpha-1 Antitrypsin Deficiency [0.03%]
异杂合α1抗胰蛋白酶缺乏症肝病风险的meta分析：重新定义
Adam M Syanda,Dimitra Georgantaki,Riona T T Linn et al.
Adam M Syanda et al.
Background: Heterozygous SERPINA1 genotypes (MZ, SZ) have historically been regarded as carrier states with limited liver relevance. Emerging evidence suggests increased liver injury, but the magnitude of risk remains unc...
Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease [0.03%]
系统评价和meta分析：排除饮食诱导并维持克罗恩病缓解
Gitika Batra,Aditi Shukla,Abhirup Chatterjee et al.
Gitika Batra et al.
Background: There is a contemporary interest in dietary therapies for the treatment of inflammatory bowel disease. We performed a systematic review and meta-analysis to analyse the clinical effectiveness of the Crohn's di...
Antiviral Therapy and Post-Resection Outcomes in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma [0.03%]
乙型肝炎病毒相关性肝细胞癌患者抗病毒治疗与术后预后关系研究
Jaehong Jeong,Jung Pyo Hong,Dong Yun Kim et al.
Jaehong Jeong et al.
Background & aims: The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after cu...
Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials. Authors' Reply [0.03%]
关于复发性急性胰腺炎试验的严重程度丰富性问题作者回复 letter
Søren S Olesen,Asbjørn M Drewes
Søren S Olesen
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group [0.03%]
乌司奴单抗治疗克罗恩病的现实世界有效性、安全性和生活质量：英国乌司奴单抗真实世界研究（Undies）研究组的结果
David Young,Cheryl Booker,Mark Samaan et al.
David Young et al.
Background and aims: While randomised controlled trials have demonstrated the efficacy of ustekinumab for treating Crohn's disease (CD), real-world effectiveness and patient experience in heterogeneous clinical population...
Letter on 'Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution'. Authors' Reply [0.03%]
关于“代偿期代谢相关脂肪性肝病肝硬化抗纤维化和缓解的药物治疗的网状 meta 分析”的来信及作者回信
Matheus Souza,Daniel Q Huang,Rohit Loomba
Matheus Souza